Atrial fibrillation/flutter in myopathies

Finsterer, Josef; Stöllberger, Claudia

doi:10.1016/j.ijcard.2007.12.041

Cited by 35 publications

(26 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[101][102][103][104][105] Specific atrial involvement can lead to sinus node disease and/or atrial arrhythmias with associated thromboembolic events. 106,107 Myotonic dystrophy type I is the most common muscular dystrophy presenting in adults. 108 Up to 15% develop atrial arrhythmias during a 10-year follow-up.…”

Section: Hereditary Muscular Dystrophiesmentioning

confidence: 99%

EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication

et al. 2016

View full text Add to dashboard Cite

Section: Hereditary Muscular Dystrophiesmentioning

confidence: 99%

EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication

et al. 2016

View full text Add to dashboard Cite

“…A study of arrhythmias in NMD described AF/atrial flutter in 139 patients with laminopathy (lamin A/C), MFM, DM1 and DM2, DMD, BMD, EDMD, LGMD, or facioscapulohumeral muscular dystrophy. 292 Stroke or embolism was observed in 6.5% of the patients, none of whom were undergoing oral anticoagulation therapy before stroke, and the authors suggested that oral anticoagulation is only indicated for NMD patients who also meet an additional risk factor (eg, HF, prior stoke or transient ischemic attack, hypertension). 292 This would appear to be at odds with recommendations for anticoagulation in patients with AF/atrial flutter.…”

Section: Anticoagulationmentioning

confidence: 99%

Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association

Feingold¹,

Mahle²,

Auerbach³

et al. 2017

Circulation

212

195

View full text Add to dashboard Cite

For many neuromuscular diseases (NMDs), cardiac disease represents a major cause of morbidity and mortality. The management of cardiac disease in NMDs is made challenging by the broad clinical heterogeneity that exists among many NMDs and by limited knowledge about disease-specific cardiovascular pathogenesis and course-modifying interventions. The overlay of compromise in peripheral muscle function and other organ systems, such as the lungs, also makes the simple application of endorsed adult or pediatric heart failure guidelines to the NMD population problematic. In this statement, we provide background on several NMDs in which there is cardiac involvement, highlighting unique features of NMD-associated myocardial disease that require clinicians to tailor their approach to prevention and treatment of heart failure. Undoubtedly, further investigations are required to best inform future guidelines on NMD-specific cardiovascular health risks, treatments, and outcomes. N euromuscular diseases (NMDs) encompass a broad spectrum of diagnoses with overlapping but distinct phenotypes. Common to many NMDs is cardiac involvement. Although the past 3 decades have seen marked advances in our understanding of many NMDs, significant gaps in knowledge remain on how best to approach cardiac care in these patients. For example, survival in Duchenne muscular dystrophy (DMD) has been extended through the use of glucocorticoid use and respiratory support, yet cardiac complications remain a significant cause of morbidity and mortality.1-3 To achieve further gains in care, we will need to improve our understanding of the pathophysiologies driving cardiac involvement in NMDs and advance treatments aimed at preventing the progression of heart failure (HF) and sudden death in NMDs. The recently published findings of an expert working group on cardiac involvement in DMD, which outlined key gaps in knowledge and made specific recommendations aimed at improving diagnosis and management, are a step toward this goal. 4 In this statement, we include a comprehensive overview of the major categories of NMDs with cardiac involvement. For each, a brief background of the gene defect(s), common clinical manifestations (particularly cardiac findings), and current therapies is summarized. Gaps in knowledge are highlighted, and where possible, clinical treatment suggestions are made by the expert writing group appointed by the American Heart Association to review the available literature. Selection of the writing group was performed in accordance with the American Heart Association's conflict-of-interest management policy. Participants volunteered to write sections relevant to their expertise and experience. CLINICAL STATEMENTS AND GUIDELINESconducted a general search of the literature, restricted to human subjects research published between 1980 and 2016. Drafts of each section were written and sent to the chair of the writing group for incorporation into a single document, which was then edited. The edited document was discussed electron...

show abstract

“…One should exercise extreme caution in the use of rate controlling and anti-arrhythmic medications. The role of anticoagulation in those with atrial arrhythmias is not well defined, with some literature suggesting a lower risk of stroke than the general population [81]. In the absence of other information patients should be risk-stratified according to CHADS2 or CHADS-Vasc scores and managed appropriately according to contemporary guidelines.…”

Section: Recommendations and Conclusionmentioning

confidence: 99%

Myotonic dystrophy and the heart: A systematic review of evaluation and management

Lau

Corbett

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

Atrial fibrillation/flutter in myopathies

Cited by 35 publications

References 54 publications

EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication

EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication

Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association

Myotonic dystrophy and the heart: A systematic review of evaluation and management

Contact Info

Product

Resources

About